Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and management dilemmas

Mult Scler. 2024 Jun;30(7):897-898. doi: 10.1177/13524585241232283. Epub 2024 Feb 22.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antigens, CD20 / immunology
  • Female
  • Humans
  • Immunologic Factors / adverse effects
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting / immunology
  • Psoriasis* / drug therapy
  • Psoriasis* / immunology
  • Rituximab / adverse effects
  • Rituximab / therapeutic use

Substances

  • Rituximab
  • Immunologic Factors
  • Antigens, CD20